Skip to main content

Day: November 16, 2023

Warner Music Group Corp. Reports Results for Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Financial HighlightsEclipsed $6 billion of total revenue for the first time in WMG’s history Acceleration in Q4 Streaming Growth Driven by Release Slate and Ad-Supported Improvement Continued Strength in Music Publishing with Double-Digit Revenue Growth for the Quarter and Full Year Strong Margin Expansion Outperformed Full-Year Expectations Achieved Robust Full-Year Operating Cash Flow Conversion of 56% in Line with TargetFor the three months ended September 30, 2023Total revenue increased 6%, or 5% in constant currency Digital revenue increased 8%, or 7% in constant currency Net income was $154 million versus $150 million in the prior-year quarter OIBDA increased 19% to $291 million versus $245 million in the prior-year quarter or 17% in constant currency Adjusted OIBDA increased 20% to $317 million versus $265 million in the prior-year...

Continue reading

WaveDancer Announces Merger Agreement with Firefly Neuroscience

– Merger to create NASDAQ-listed, commercial-stage AI-Enabled medical technology company focused on bringing FDA-cleared Brain Network Analytics platform to NASDAQ Capital Markets FAIRFAX, Va., Nov. 16, 2023 (GLOBE NEWSWIRE) — WaveDancer, Inc. (“WaveDancer”) (NASDAQ: WAVD) today announced that it has entered into a definitive merger agreement with privately held, commercial-stage, medical technology company, Firefly Neuroscience, Inc. (“Firefly”), to combine the companies in an all-stock transaction. The combined company will focus on continuing to develop and commercialize Firefly’s Artificial Intelligence driven Brain Network Analytics (BNA™) platform, which was previously cleared by the U.S. Food and Drug Administration (“FDA”). Upon closing, which is currently expected in Q1-2024, the combined company is expected to...

Continue reading

Q32 Bio and Homology Medicines Announce Merger Agreement

—The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio’s two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders– –Q32 Bio has re-acquired worldwide development and commercial rights to bempikibart, an anti-IL-7Rα antibody inhibiting IL-7 and TSLP-mediated signaling, and remains on-track to report multiple topline Phase 2 results in 2H’24– –Concurrent $42 million private placement investment with new and existing investors supports clinical development through multiple milestones, including key Phase 2 readouts for bempikibart, initial ADX-097 proof-of-concept data by year-end 2024 and ADX-097 topline results in 2H’25– –Combined...

Continue reading

Gilat Completes Acquisition of DataPath, Inc.

The acquisition represents a strong step forward in Gilat’s strategy to increase its presence in the growing defense communications market PETAH TIKVA, Israel, Nov. 16, 2023 (GLOBE NEWSWIRE) — Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that it has completed the acquisition of DataPath, Inc., a market leader in trusted communications for the US DoD Military and Government sectors. The transaction was approved by the Gilat Board of Directors and by DataPath’s Board of Directors and stockholders earlier this year, and it has received regulatory approvals, including the receipt of clearance from the Committee on Foreign Investment in the United States (CFIUS). “This acquisition is a strong step ahead in Gilat’s strategy to...

Continue reading

AYR Wellness Reports Third Quarter 2023 Results

Revenue up 5% Y/Y to $114.4 Million, Excluding Discontinued Operations GAAP Loss from Operations Improved 92% Y/Y to ($1.5) Million, Excluding Discontinued Operations Generated over $20 Million of Operating Cash Flow in the Third Quarter Adjusted EBITDA1 up 52% Y/Y to $28.4 Million, with Adjusted EBITDA Margin of 25% MIAMI, Nov. 16, 2023 (GLOBE NEWSWIRE) — AYR Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF) (“AYR” or the “Company”), a leading vertically integrated U.S. multi-state cannabis operator (“MSO”), is reporting financial results for the third quarter ended September 30, 2023. Unless otherwise noted, all results are presented in U.S. dollars. The following financial measures are reported as results from continuing operations due to the sale of the Company’s business in Arizona in March 2023, which are reported as discontinued...

Continue reading

Guardian Capital Announces November 2023 Distributions for Guardian Capital ETFs

TORONTO, Nov. 16, 2023 (GLOBE NEWSWIRE) — Guardian Capital LP announces the following regular cash distributions for the period ending November 30, 2023, in respect of the ETF series of the Guardian Capital funds listed below (the “Guardian Capital ETFs”). In each case, the distribution will be paid on November 30, 2023 to unitholders of record on November 24, 2023. The ex-dividend date in each case is November 23, 2023, with the exception of Guardian Ultra-Short Canadian T-Bill Fund and Guardian Ultra-Short U.S. T-Bill Fund which have an ex-dividend date of November 24, 2023.Guardian Capital ETFs Series of ETF Units Distribution Frequency TSX Trading Symbol Distribution Amount (per ETF Unit)Guardian Directed Equity Path Portfolio Hedged ETF Units Monthly GDEP CAD$0.07461Guardian Directed Equity Path Portfolio Unhedged...

Continue reading

Teleflex Announces First Patient Enrollment in ACCESS-MANTA™ Registry

Registry Intends to Examine Contemporary On-Label Use of the MANTA™ Vascular Closure Device Including Appropriate Patient Selection and Proper Vascular Access WAYNE, Pa., Nov. 16, 2023 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the first patient enrollment in a clinical registry that is intended to examine and collect data on outcomes of contemporary on-label use of the MANTA™ Vascular Closure Device (VCD) in standard of care transcatheter aortic valve replacement (TAVR) procedures. The registry will include appropriate patient selection and proper vascular access. Enrolling at least 250 patients in up to 15 major TAVR institutions across the US and Canada, the ACCESS-MANTA™ Registry is an international, multicenter, prospective,...

Continue reading

SpringWorks Therapeutics Announces Positive Topline Results from the Phase 2b ReNeu Trial of Mirdametinib in NF1-PN

– Confirmed objective response rate of 52% in pediatric patients and 41% in adult patients, as assessed by Blinded Independent Central Review – – Mirdametinib treatment resulted in deep and durable responses and significant improvements in key secondary patient-reported outcome measures – – Mirdametinib was generally well tolerated with low rates of Grade 3+ adverse events – – Additional data expected to be presented at medical conference and NDA submission to the U.S. FDA planned in the first half of 2024 – – Company to host conference call today at 8:30 a.m. Eastern Time – STAMFORD, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced positive...

Continue reading

MacGregor has secured another significant RoRo equipment order for two Pure Car and Truck Carriers

MacGregor_hoistable_ramp_PCTCMacGregor hoistable rampCARGOTEC CORPORATION, PRESS RELEASE, 16 NOVEMBER 2023 AT 1:00 PM EET MacGregor, part of Cargotec, is supplying comprehensive packages of RoRo equipment for another two PCTC vessels to be built by Hyundai Mipo Dockyard Co. Ltd in South Korea. The significant repeat order was booked into Cargotec’s 2023 fourth quarter orders received. The vessels are scheduled to be delivered to the owner during the first half of 2027. MacGregor’s scope of supply encompasses design, supply, and installation support of a complete hardware delivery to both vessels: quarter ramp, side ramp, four deck levels of liftable car deck panels, several internal ramps, and pilot- and bunker doors. MacGregor was selected to supply the RoRo and car deck equipment for the vessels as a repeat order due to its...

Continue reading

Radware Provides Network and Application Security for One of North America’s Busiest Airports

Combines forces with partner Wipro to bolster data center and application defenses MAHWAH, N.J., Nov. 16, 2023 (GLOBE NEWSWIRE) — Radware® (NASDAQ: RDWR), a leading provider of cyber security and application delivery solutions, today announced that it was selected to provide network and application security to protect the data centers for one of North America’s top 20 busiest airports. Radware’s Cloud DDoS Protection Service and Cloud Application Protection Services were purchased to increase data center and application defenses and speed time to protection. Radware secured the new customer agreement in combination with partner Wipro Limited, a global leading technology services and consulting company. “These comprehensive services will help the customer more effectively mitigate DDoS attacks, neutralize security risks, and safeguard...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.